TNFRSF17 and plasma cell myeloma: Belantamab mafodotin (GSK2857916, belamaf) is a first-in-class ADC for the treatment of multiple myeloma featuring the humanized anti-BCMA antibody J6M0 with a defucosylated Fc portion and monomethyl auristatin F (MMAF, mafodotin) as its effector molecule [73].